Atara gets positive CHMP opinion for Ebvallo; Q3 net loss $84.1M

Atara Biotherapeutics, Inc.

CHMP positive opinion for Ebvallo in EBV+ PTLD; EC approval expected by end 2022.
Cash $265.4M; expects operating runway into Q1 2024 with Pierre Fabre milestone.
Q3 net loss $84.1M ($0.82/diluted share) vs $84.7M ($0.90) YoY; R&D $70.2M.
ATA188 MRI data show less brain atrophy, potential remyelination in progressive MS patients with CDI.
Tab-cel safety consistent; ORR 51.2% in Phase 3 ALLELE; seeking US commercialization partner.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atara Biotherapeutics, Inc. reported financial results for the third quarter 2022.

Period: the third quarter 2022
Result: reported results

Exact text from the filing

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.